

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07039-409US1	Application No. 10/561,014
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Shuchong Pan et al.	
		Filing Date December 16, 2005	Group Art Unit 1649
(37 CFR §1.98(b))			

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	4,034,074	07/05/77	Miles			
	2	4,098,876	07/04/78	Piasio et al.			
	3	4,233,402	11/11/80	Maggio et al.			
	4	4,996,143	02/26/91	Heller et al.			
	5	5,114,923	05/19/92	Seilhamer et al.			
	6	5,296,347	03/22/94	LaMotte, III			
	7	5,565,322	10/15/96	Heller			
	8	5,580,859	12/03/96	Felgner et al.			
	9	5,583,108	12/10/96	Wei et al.			
	10	5,589,466	12/31/96	Felgner et al.			
	11	5,849,489	12/15/98	Heller			
	12	6,124,430	09/26/00	Mischak et al.			
	13	6,162,603	12/19/00	Heller			
	14	6,376,207	04/23/02	Mischak et al.			

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	15	WO 84/03825	10/11/84	WIPO				
	16	WO 00/71576	11/30/00	WIPO				
	17	WO 01/44284	06/21/01	WIPO				

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	18	Abdelhafiz, "Heart failure in older people: causes, diagnosis and treatment," <u>Age Ageing</u> , 2002, 31(1):29-36
	19	Best et al., "Dendroaspis natriuretic peptide relaxes isolated human arteries and veins," <u>Cardiovas. Res.</u> , 2002, 55:375-384
	20	Burger and Burger, "BNP in decompensated heart failure: Diagnostic, prognostic and therapeutic potential," <u>Curr. Opin. Investig. Drugs</u> , 2001, 2(7):929-35

Examiner Signature /Chang-Yu Wang/	Date Considered 11/30/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07039-409US1	Application No. 10/561,014
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Shuchong Pan et al.	
		Filing Date December 16, 2005	Group Art Unit 1649
(37 CFR §1.98(b))			

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	21	Chaurand et al., "Peptide and Protein Identification by Matrix-Assisted Laser Desorption Ionization (MALDI) and MALDI-Post-Source Decay Time-of-Flight Mass Spectrometry," <u>J. Am. Soc. Mass Spectrom.</u> , 1999, 10(2):91-103
	22	Cole et al., "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer," <u>Monoclonal Antibodies and Cancer Therapy</u> , 1985, Alan R. Liss, Inc., pp. 77-96
	23	Cote et al., "Generation of human monoclonal antibodies reactive with cellular antigens," <u>Proc. Natl. Acad. Sci. USA</u> , 1983, 80:2026-2030
	24	Cowie and Mendez, "BNP and Congestive Heart Failure," <u>Prog. Cardiovasc. Dis.</u> , 2002, 44(4):293-321
	25	Gevaert et al., "Protein identification based on matrix assisted laser desorption/ionization-post source decay-mass spectrometry," <u>Electrophoresis</u> , 2001, 22(9):1645-51
	26	Guatelli et al., "Isothermal, <i>in vitro</i> amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication," <u>Proc. Natl. Acad. Sci. USA</u> , 1990, 87:1874-1878
	27	Huse et al., "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," <u>Science</u> , 1989, 246:1275-1281
	28	Hyrup and Nielsen, "Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential Applications," <u>Bioorgan. Med. Chem.</u> , 1996, 4:5-23
	29	Köhler and Milstein, "Continuous cultures of fused cells secreting antibody of predefined specificity," <u>Nature</u> , 1975, 256:495-497
	30	Kozbor and Roder, "The production of monoclonal antibodies from human lymphocytes," <u>Immunology Today</u> , 1983, 4:72-79
	31	Lewis, "PCR's Competitors Are Alive and Well and Moving Rapidly Towards Commercialization," <u>Genetic Engineering News</u> , 1992, 12(9):1-3
	32	Peacock, "The B-type natriuretic peptide assay: a rapid test for heart failure," <u>Cleve. Clin. J. Med.</u> , 2002, 69(3):243-251
	33	Richards et al., "BNP in hormone-guided treatment of heart failure," <u>Trends Endocrinol. Metab.</u> , 2002, (5):151-155
	34	Sagnella, "Practical implications of current natriuretic peptide research," <u>J. Renin. Angiotensin Aldosterone Syst.</u> , 2000, 1(4):304-315
	35	Ausubel et al. (eds.), <u>Short Protocols in Molecular Biology</u> , 1992, Chapters 8 and 11, Green Publishing Associates and John Wiley & Sons
	36	Summerton and Weller, "Morpholino Antisense Oligomers: Design, Preparation, and Properties," <u>Antisense Nucleic Acid Drug Dev.</u> , 1997, 7:187-195
	37	Tremblay et al., "Biochemistry and physiology of the natriuretic peptide receptor guanylyl cyclases," <u>Mol. Cell. Biochem.</u> , 2002, 230(1-2):31-47
	38	Walther et al., "Natriuretic peptide system in fetal heart and circulation," <u>J. Hypertens.</u> , 2002, 20(5):786-791
	39	Weiss, "Hot Prospect for New Gene Amplifier," <u>Science</u> , 1991, 254:1292-1293

Examiner Signature  /Chang-Yu Wang/	Date Considered  11/30/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	